iX Biopharma Ltd. (SGX: 42C)
Singapore flag Singapore · Delayed Price · Currency is SGD
0.0240
-0.0010 (-4.00%)
At close: Nov 12, 2024

iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 20.32 million. The enterprise value is 23.67 million.

Market Cap 20.32M
Enterprise Value 23.67M

Important Dates

Earnings Date n/a
Ex-Dividend Date n/a

Share Statistics

iX Biopharma has 883.34 million shares outstanding. The number of shares has increased by 0.33% in one year.

Current Share Class n/a
Shares Outstanding 883.34M
Shares Change (YoY) +0.33%
Shares Change (QoQ) +0.25%
Owned by Insiders (%) 41.96%
Owned by Institutions (%) 0.10%
Float 480.70M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.96
PB Ratio 4.07
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -2.19
EV / Sales 3.97
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -3.47

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.20.

Current Ratio 0.89
Quick Ratio 0.65
Debt / Equity 1.20
Debt / EBITDA n/a
Debt / FCF -0.76
Interest Coverage -16.96

Financial Efficiency

Return on equity (ROE) is -106.91% and return on invested capital (ROIC) is -31.51%.

Return on Equity (ROE) -106.91%
Return on Assets (ROA) -23.69%
Return on Capital (ROIC) -31.51%
Revenue Per Employee 141,881
Profits Per Employee -257,000
Employee Count 42
Asset Turnover 0.30
Inventory Turnover 4.20

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -45.45% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -45.45%
50-Day Moving Average 0.03
200-Day Moving Average 0.04
Relative Strength Index (RSI) 38.57
Average Volume (20 Days) 266,920

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 5.96 million and -10.79 million in losses. Loss per share was -0.01.

Revenue 5.96M
Gross Profit 1.05M
Operating Income -7.50M
Pretax Income -9.99M
Net Income -10.79M
EBITDA -7.08M
EBIT -7.50M
Loss Per Share -0.01
Full Income Statement

Balance Sheet

The company has 1.84 million in cash and 5.20 million in debt, giving a net cash position of -3.36 million or -0.00 per share.

Cash & Cash Equivalents 1.84M
Total Debt 5.20M
Net Cash -3.36M
Net Cash Per Share -0.00
Equity (Book Value) 4.34M
Book Value Per Share 0.01
Working Capital -795,000
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.55 million and capital expenditures -274,000, giving a free cash flow of -6.83 million.

Operating Cash Flow -6.55M
Capital Expenditures -274,000
Free Cash Flow -6.83M
FCF Per Share -0.01
Full Cash Flow Statement

Margins

Gross margin is 17.59%, with operating and profit margins of -125.78% and -181.14%.

Gross Margin 17.59%
Operating Margin -125.78%
Pretax Margin -167.56%
Profit Margin -181.14%
EBITDA Margin -118.88%
EBIT Margin -125.78%
FCF Margin -114.57%

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.33%
Shareholder Yield -0.33%
Earnings Yield -61.30%
FCF Yield -33.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

iX Biopharma has an Altman Z-Score of -8.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -8.52
Piotroski F-Score n/a